Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,084 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,469 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00626496 | Family Study of Lymphoproliferative Disorders | recruiting | — | 3,000 | Mayo ClinicOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06520098 | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(Benefit VA) | recruiting | Phase 2 | 100 | VA Office of Research and DevelopmentFED | 1 | Oct 14, 2025 |
| clinicaltrials |
| NCT02909036 | Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | active not recruiting | Phase 1 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT03016806 | Umbilical Cord Blood Transplantation From Unrelated Donors | recruiting | — | 30 | University of RochesterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05270057 | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies(LONCA) | active not recruiting | Phase 1 | 11 | Medical College of WisconsinOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT05940272 | Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers | recruiting | N/A | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT07202052 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202065 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202078 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202091 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT02153580 | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | active not recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07207785 | PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma(FIL_PUMA) | not yet recruiting | Phase 2 | 56 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07208981 | Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL | recruiting | Phase 2 | 169 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05556720 | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial(BOOST-IC) | active not recruiting | Phase 3 | 960 | Monash UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07205523 | High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)(HALO-SCT) | recruiting | — | 1,000 | Yigeng Cao,MD,PhDOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07206264 | Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment(ADAPT-MCL) | not yet recruiting | Phase 2 | 45 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05878184 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | active not recruiting | Phase 1 | 16 | Sana BiotechnologyINDUSTRY | 2 | Oct 2, 2025 | clinicaltrials |
| NCT07039877 | Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients | recruiting | Phase 2 | 12 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05932680 | Limited-duration Teclistamab | recruiting | Phase 2 | 75 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05971251 | Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 24 | University of Alabama at BirminghamOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT03327597 | Iceland Screens, Treats or Prevents Multiple Myeloma(iStopMM) | active not recruiting | N/A | 80,761 | University of IcelandOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06925555 | Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS | not yet recruiting | Phase 2 | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198373 | Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma | not yet recruiting | — | 40 | Beijing GoBroad HospitalOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT07198464 | Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma | not yet recruiting | N/A | 30 | Zhengzhou UniversityOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT07199296 | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment | recruiting | Phase 2 | 45 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07199855 | Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia | active not recruiting | Phase 2 | 24 | Zhejiang UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03147885 | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 43 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04479267 | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma | active not recruiting | Phase 2 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06979076 | A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL | not yet recruiting | Phase 1 / Phase 2 | 12 | MingSight Pharmaceuticals, IncINDUSTRY | 0 | Sep 29, 2025 | clinicaltrials |
| NCT05192486 | A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 1 / Phase 2 | 12 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05485753 | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | active not recruiting | Phase 1 / Phase 2 | 7 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05621096 | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 33 | University of NebraskaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05722418 | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma(CaMMouflage) | recruiting | Phase 1 | 50 | Caribou Biosciences, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06409767 | Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.(ALHERT) | recruiting | N/A | 2,224 | University Hospital, AngersOTHER_GOV | 1 | Sep 24, 2025 | clinicaltrials |
| NCT07187960 | Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma | not yet recruiting | Phase 3 | 228 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06037018 | Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies | recruiting | Phase 1 | 44 | CytoCares IncINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07185477 | A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma(QLS32015) | not yet recruiting | Early Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 22, 2025 | clinicaltrials |
| NCT04697940 | Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL | active not recruiting | Phase 1 / Phase 2 | 33 | Han weidongOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06120166 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research | recruiting | Early Phase 1 | 18 | He HuangOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05643235 | Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors | recruiting | N/A | 50 | Northwell HealthOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05823571 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06381141 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | active not recruiting | Phase 1 | 30 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07181239 | Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients | not yet recruiting | Phase 3 | 280 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06487247 | HEME Home Transfusion Program | recruiting | N/A | 700 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07107204 | A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 116 | Biotroy TherapeuticsINDUSTRY | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07168291 | Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma | not yet recruiting | Early Phase 1 | 3 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04162353 | BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma | recruiting | Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04447716 | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment | active not recruiting | Phase 1 | 4 | Thomas Jefferson UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Oct 14, 2025source: clinicaltrials